CordenPharma – Talk Bio

Viking Signs $150M Manufacturing Agreement with CordenPharma for Obesity Drug Candidate

1 month ago talkbio0Tagged CordenPharma, GLP-1/GIP, Manufacturing, Obesity, Viking, VK2735

Viking Therapeutics, CordenPharma, VK2735, obesity drug, manufacturing agreement, GLP-1/GIP dual agonist

Viking Therapeutics Signs $150 Million Manufacturing Deal with CordenPharma for Obesity Drug VK2735

1 month ago talkbio0Tagged alpha 1-antitrypsin, Capacity, Contract agreement, CordenPharma, Fill/finish, GLP-1/GIP Dual Agonist, Obesity, oral formulations, production, subcutaneous, Viking, VK2735

Viking Therapeutics, CordenPharma, VK2735, Obesity drug, GLP-1/GIP dual agonist, Contract manufacturing, API production, Fill/finish capacity, Subcutaneous and oral formulations

CordenPharma Invests €900M in Peptide Manufacturing Expansion to Meet Rising Demand for GLP-1 Medications

9 months ago talkbio0Tagged CordenPharma, Diabetes, Drug Industry, expansion, Glucagon-Like Peptide 1, Investments, Obesity, Peptides

CordenPharma, GLP-1, peptide manufacturing, expansion, investment, diabetes, obesity, pharmaceutical industry